NDAINTRAVENOUSPOWDER
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows PET.
Indications (1)
Loss of Exclusivity
LOE Date
Mar 9, 2036
121 months away
Patent Expiry
Mar 9, 2036